非布司他治疗高尿酸血症、高脂血症患者血管内皮功能损伤的临床研究  

Clinical study of febuxostat intervention in treatment of hyperuricemia and vascular endothelial dysfunction in patients with hyperlipidemia

作　　者：陈士芳[1] 许瑜佳[1] 殷丽娟 陶渊璆 梅珏[1] 王友庆[1] 

机构地区：[1]浙江省湖州市中心医院风湿免疫科,湖州313000

出　　处：《中华内分泌外科杂志》2017年第5期409-413,共5页Chinese Journal of Endocrine Surgery

基　　金：湖州市科技局科技项目（2016GYB24）

摘　　要：目的观察非布司他干预高尿酸血症、高脂血症患者的治疗效果，为优化临床治疗方案提供有效依据。方法收集2015年3月至2016年3月湖州市中心医院住院的伴有高脂血症的高尿酸血症痛风患者的一般资料。共80例纳入研究，采用随机数字表法随机分为观察组和对照组，每组各40例。观察组服用40mg非布司他片，1次／d；对照组患者服用100mg别嘌呤醇片，3次／d，治疗24周。观察2组临床症状及体征，分别于治疗前（入院时）、治疗12周、治疗24周检测血尿酸、血脂及血管内皮因子可溶性细胞间黏附分子（sICAM-1）、内皮素-1（ET-1）水平，记录各组出现肝肾功能损伤、不良反应的情况。结果观察组与对照组病情均有所好转，观察组患者尿酸、甘油三脂、血管内皮因子sICAM-1、ET-1水平均下降。且与对照组相比差异有统计学意义（P〈0．05），治疗期间2组的不良反应均为一过性，观察组肝肾功能损伤、药物副作用发生率较对照组降低．除了皮疹的发生率2组差异有统计学意义外，余各项差异无统计学意义（P〉0．05）。结论非布司他干预治疗高尿酸血症、高脂血症患者疗效好，且不良反应较少，安全性较高，可在临床深入推广。Objective To evaluate the clinical efficiency of febuxostat on hyperuricemia and hyperlipi- demia, provide evidences for the option of clinical treatment. Methods From Mar. 2015 to Mar. 2016, 80 pa- tients with hyperuricemia and hyperlipidemia were enrolled to this study, and they were randomly divided into observation group and control group by random number table , each group with 40 cases. The observation group received 40 mg of fenbuterol tablets once a day. The control group received 100 mg aIlopurinol tablets three times a day. The levels of serum uric acid, lipids, endothelium-soluble intercellular adhesion molecule-1 （sICAM-1） and en- dothelium （ET-1） were measured at the baseline,12 weeks after treatment and 24 weeks after treatment. Meanwhile, the liver and kidney function damage and adverse reactions were recorded. Results After treatment, the levels of uric acid, blood lipid, sICAM-1 and ET-1 were decreased in two groups, and there was significant difference between them （P〈0.05）. The adverse effects of the two groups were transient. The incidence of liver or kidney damage, side effect of drug in observation group was lower than that in the control group, and there was no sig- nificant difference between the two groups （190.05）, except the incidence of rash. Conclusion Febuxostat interven- tion in treatment of patients with hyperuricemia and hyperlipidemia is safe and efficient.

关 键 词：非布司他 高尿酸血症 高脂血症 血管内皮功能 

分 类 号：R589[医药卫生—内分泌]